Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 78.77 |
| Open | 79.00 |
| Bid | 78.73 x 600 |
| Ask | 78.80 x 500 |
| Day's range | 78.26 - 79.21 |
| 52-week range | 62.07 - 87.87 |
| Volume | |
| Avg. volume | 6,989,616 |
| Market cap | 98.006B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 96.00 |
| EPS (TTM) | 0.82 |
| Earnings date | 07 Nov 2024 |
| Forward dividend & yield | 3.08 (3.91%) |
| Ex-dividend date | 13 Sept 2024 |
| 1y target est | 82.29 |
Insider MonkeyGilead Sciences, Inc. (GILD): Are Hedge Funds Bullish On This Biotech Stock?
We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1,” the […]
Business WireGilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
FOSTER CITY, Calif., September 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presentations include: initial results from two cohorts of the EVOKE-02 study of Trodelvy® (sacituzumab govitecan-hziy
Simply Wall St.Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 86% of the company
Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...
